Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of NDO, confirmed by urodynamics~* Practicing clean intermittent catheterization (CIC)~* Currently on treatment with an antimuscarinic drug~Exclusion Criteria:~* Known genitourinary condition (other than NDO) that may cause incontinence~* Bladder augmentation surgery~* Current Faecal impaction~* Electro-stimulation therapy within 2 weeks prior to screening and at any time during the study~* Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention~* Reflux grade 3 or 4~* Current urinary tract infection (UTI)~* Subject has severe renal impairment (glomerular filtration rate \< 30 ml/min)~* Subject has severe hepatic impairment (Child-Pugh score \> 9).~* Subject has received intra-vesical botulinum toxin within 9 months prior to screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Solifenacin succinate (Type: EXPERIMENTAL): Participants aged 5 years to \< 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52).

Based on this trial design, predict the completion outcome and termination type (if applicable).